<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02092896</url>
  </required_header>
  <id_info>
    <org_study_id>2012-002526-67</org_study_id>
    <secondary_id>2012-002526-67</secondary_id>
    <nct_id>NCT02092896</nct_id>
  </id_info>
  <brief_title>Liraglutide as add-on to Insulin in Type 1 Diabetes</brief_title>
  <acronym>T1DMLIRA</acronym>
  <official_title>Treatment With Liraglutide as add-on to Insulin in Type 1 Diabetic Patients. Effects on Glycemic Control and Counterregulation and Cognitive Performance During Hypoglycaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NNF Center for Basal Metabolic Research, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hillerod Hospital, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danish PhD schools of Molecular Metabolism and Endocrinology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to:

      Part 1:

      To investigate how 12 weeks treatment with liraglutide affects glycemic control in poorly
      controlled patients and how the treatment affects gastric emptying rate during hypoglycemia.

      Part 2:

      To investigate how 12 weeks treatment of type 1 diabetic patients with liraglutide affects
      counterregulatory hormones and cognitive performance during hypoglycemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in HbA1c (glycosylated haemoglobin)</measure>
    <time_frame>Week 0, week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in EEG and cognitive performances</measure>
    <time_frame>week 0, week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in gastric emptying rate</measure>
    <time_frame>week 0, week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in glycemic control (CGM)</measure>
    <time_frame>week 0, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total daily insulin dose</measure>
    <time_frame>week 0, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in the counterregulatory hormone responses during hypoglycemia</measure>
    <time_frame>week 0, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body weight</measure>
    <time_frame>week 0, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in auditory evoked potentials (AEP) during hypoglycemia</measure>
    <time_frame>week 0, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in corrected QTc-interval (QTc) during hypoglycemia</measure>
    <time_frame>week 0, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in hypoglycemic symptom score</measure>
    <time_frame>week 0, week 12</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Frequency of Hypoglycemic episodes</measure>
    <time_frame>Week 0, week 12</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Placebo + Insulin + Study 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study 2: Cognitive performance test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide + Insulin + Study 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study 2: Cognitive performance test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide + Insulin + Study 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study 1: Gastric emptying test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Insulin + Study 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study 1: Gastric emptying test</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.</description>
    <arm_group_label>Liraglutide + Insulin + Study 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.</description>
    <arm_group_label>Placebo + Insulin + Study 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.</description>
    <arm_group_label>Placebo + Insulin + Study 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.</description>
    <arm_group_label>Liraglutide + Insulin + Study 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-70 years

          -  BMI: 18-28

          -  HbA1c ≥ 8 %

          -  No residual β-cell function (glucagon test with c-peptide &lt; 60 pM)

          -  Caucasian

          -  Diagnosed with type 1 diabetes at 5 to 40 years of age (both inclusive).

          -  Remission phase must be completed

          -  Female participants must use adequate contraception

          -  Informed consent

        Exclusion Criteria:

          -  Overt diabetes complications; creatinin &gt; 130 µM, proliferative retinopathy,
             macroalbuminuria.

          -  Autonomic neuropathy (RR-variation &lt;/=10 beats/min) and/or Orthostatic hypotension
             (OH).

          -  Anemia, Hb concentration; female &lt;7.0 mmol/l, male&lt;8.0 mmol/l

          -  Pregnancy or lactation

          -  Epilepsy

          -  Use of antiepileptic medication

          -  Use of beta blockers

          -  Previously apoplexy cerebri.

          -  Any use of benzodiazepine within the last month

          -  Any use of neuroleptic drugs within the last six months

          -  Self-perceived hearing loss

          -  Alcohol or drug abuse

          -  Allergy to the medication or placebo.

          -  Treatment with any medication affecting glucose metabolism.

          -  Any disorder which in the investigators opinion could interfere with the safety and
             results of the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian SS Frandsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Endocrinology, Hvidovre University Hospital</name>
      <address>
        <city>Hvidovre</city>
        <state>Copenhagen</state>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2014</study_first_submitted>
  <study_first_submitted_qc>March 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2014</study_first_posted>
  <last_update_submitted>March 31, 2015</last_update_submitted>
  <last_update_submitted_qc>March 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Christan SS Frandsen, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Diabetes Mellitus, Type 1</keyword>
  <keyword>Glucose Metabolism Disorders</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Cognitive performance</keyword>
  <keyword>Hypoglycemia</keyword>
  <keyword>Insulin</keyword>
  <keyword>Glucagon-Like Peptide 1</keyword>
  <keyword>Hypoglycemic Agents</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Incretins</keyword>
  <keyword>Hormones</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

